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Abstract: Fibromyalgia syndrome (FMS) is a chronic condition characterized by widespread 
pain, tender points, fatigue, and sleep disturbance. FMS leads to high disability levels, poor 
quality of life, and extensive use of medical care. Effective pharmacological treatment options 
are rare, and treatment effects are often of limited duration. Duloxetine is a new selective sero-
tonin and norepinephrine reuptake inhibitor that is licensed for the treatment of pain in diabetic 
neuropathy. So far two randomized, placebo-controlled trials have investigated the short-term 
safety and efﬁ  cacy of duloxetine 60 mg/day and 120 mg/day in patients suffering from FMS 
over a period of 12 weeks. Both dosages were superior to placebo in pain relief, and improve-
ment in quality of life and depressive symptoms. The analgesic effect was largely independent 
of the antidepressant action of duloxetine. The higher dose of 120 mg/day further reduced the 
tender point count and elevated the tender point pain thresholds. Only mild to moderate adverse 
effects were reported. Duloxetine 60 mg/day and 120 mg/day has proven to be beneﬁ  cial in 
the treatment of FMS symptoms. As true for other antidepressants further studies are needed 
to assess the long-term efﬁ  cacy and safety of duloxetine as an additional pharmacological 
treatment option in FMS.
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Introduction
Fibromyalgia syndrome (FMS) is deﬁ  ned as a condition including chronic widespread 
pain (ie, pain in all four body quadrants for more than 3 months) and at least 11 out of 
18 tender points that are painful upon digital palpation with 4 kg. These criteria were 
developed by the American College of Rheumatology (ACR) (Wolfe et al 1990) to 
provide a consensus deﬁ  nition for FMS, establish new criteria for the classiﬁ  cation of 
FMS, to study the relation of “primary” and “secondary” FMS, and to assess the strength 
of previous deﬁ  nition criteria. In addition to pain and tenderness, most patients with 
FMS suffer from accompanying symptoms like fatigue, poor sleep, gastrointestinal 
disturbances, anxiety, or depression. Population-based estimates of the prevalence of 
FMS range from 0.5% to 5.8% (Gran 2003). Women are more frequently affected 
than men (Wolfe et al 1995) and patients diagnosed with FMS cause considerable 
direct (health care use) (White et al 1999; Penrod et al 2004; Boonen et al 2005) and 
indirect costs (sick-leave, disability pension) (Henriksson et al 2005). Effective treat-
ment options are therefore needed not only for medical but also for economic reasons 
(Robinson and Jones 2006).
Numerous pharmacologic and non-pharmacologic treatment options are offered 
to (Robinson and Jones 2006) and are used by patients suffering from FMS (Bennett 
et al 2007). To date over 500 peer-reviewed articles on the therapy of FMS have been 
published (Goldenberg and Smith 2003), yet no treatment has proven potent enough to 
alleviate the entire scope of symptoms and disabilities associated with FMS (van Koulil 
et al 2007) – a goal that may be unrealistic considering the variability of symptoms. Neuropsychiatric Disease and Treatment 2008:4(3) 526
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In addition, treatment response is usually partial and limited 
to patient subgroups. To provide patients and physicians an 
orientation within the continuously growing number of stud-
ies on the pharmacological treatment of FMS, evidence-based 
guidelines have been published by the American Pain Society 
(APS) (Goldenberg et al 2004) and the European League 
Against Rheumatism (EULAR) (Carville et al 2008). Both 
gave the highest level of recommendation to treatment of 
FMS symptoms with antidepressants. It is important to note 
that none of the antidepressants investigated is licensed for 
the treatment of FMS. To date, the only drug licensed by the 
US Food and Drug administration (FDA) for the treatment 
of FMS symptoms is the anticonvulsant pregabalin, which 
was effective in two randomized, double-blind, placebo-
controlled trials (RCT) (Crofford et al 2005; Arnold et al 
2007). However, some antidepressants are approved for the 
treatment of chronic pain, and an application has been ﬁ  led 
with the FDA for the selective serotonin and norepinephrine 
reuptake inhibitor (SNRI) duloxetine.
Duloxetine is a “pure” SNRI without actions on further 
receptors, thus avoiding cholinergic or adrenergic side effects 
(Bymaster et al 2001). It is a safe and efﬁ  cacious antide-
pressant with only mild adverse effects (Detke et al 2002; 
Goldstein et al 2002). A recent study could show an effect 
of duloxetine on painful physical symptoms associated with 
depression (Goldstein et al 2004). Furthermore, duloxetine 
is effective in the treatment of painful diabetic peripheral 
neuropathy, independent of depression (Goldstein et al 2005; 
Raskin et al 2005). It is licensed for the treatment of major 
depression and generalized anxiety disorders in adults, and 
for painful diabetic peripheral neuropathy.
Duloxetine 120 mg/day reduces 
pain in FMS
The effect of duloxetine on symptoms of FMS has been 
investigated in two RCTs. The ﬁ  rst trial was a multi-center 
RCT with parallel design lasting over 12 weeks (Arnold 
et al 2004). Of 555 patients screened, 207 (37.3%) were 
randomized. Of these, 124 (59.9%) completed the study. The 
placebo group consisted of 103 patients, of whom 66 (64.1%) 
completed the trial while the duloxetine group comprised 104 
patients of whom 58 (55.7%) completed the study. The mean 
age of patients was 49.9 years, 88.5% of the study population 
were women, and 88.5% Caucasian. Of the study population, 
35.6% reported major depression.
Duloxetine was applied in a daily dosage of 120 mg (ie, 60 mg 
twice a day). Patients started with 20 mg/day and titrated 
to 60 mg twice a day within two weeks. The patients were 
assessed regularly at 10 visits. Paracetamol (up to 2 g/day) 
and acetyl salicylic acid (up to 325 mg/day) were the only 
analgesics allowed. There was a wash out period of 7 days 
for antidepressants before the second visit (exceptions: 
monoaminoxidase inhibitors a 14-day wash out; ﬂ  uoxetine 
a 30-day wash out). A number of exclusion criteria were 
observed, such as concomitant rheumatologic and cardiac 
diseases, the involvement in disability reviews, and failure 
to respond to more than two antidepressants from different 
classes for depression or FMS.
The main goal was to examine the efﬁ  cacy and safety 
of duloxetine in the treatment of FMS symptoms. Primary 
outcome measures were assessed using the Fibromyalgia 
Impact Questionnaire (FIQ), which gave the FIQ total score 
and FIQ pain score. Secondary outcome measures were FIQ 
fatigue, morning tiredness, and stiffness. The Brief Pain 
Inventory (BPI) measured the average pain severity score 
over the past 24 hours and the average interference score of 
FMS symptoms with items such as general daily activity, 
mood, or walking activity. The Clinical Global Impression of 
Severity scale (CGIS) and the Patient Global Assessment of 
Improvement scale (PGAI) were further applied. Quality 
of life measures covered the Quality of Life in Depression 
Scale total score (QLDS), the Shehaan Disability Scale total 
score (SDS), and the Medical Outcomes Study Short Form 36 
(SF-36). Furthermore, tender point number and tender point 
pain thresholds were assessed using an algometer.
Patients in the duloxetine group more frequently reported 
adverse effects (90.4%: duloxetine group vs 74.8%: placebo 
group), which were mainly insomnia, xerostomia (dry mouth), 
and constipation. The severity of most drug-related adverse 
effects was mild to moderate; severe treatment-emergent 
adverse events were equally present in the duloxetine and 
placebo group. Patients treated with duloxetine had a small 
increase from baseline to endpoint in heart rate. No clinically 
relevant changes in laboratory tests were observed. There 
were 18 study drop outs due to side effects in the duloxetine 
group and 11 in the placebo group, with no signiﬁ  cant 
intergroup difference.
Except for a few items (FMS associated fatigue; FIQ pain, 
fatigue, and tiredness on awakening scores; Beck Anxiety 
Inventory total score) duloxetine 120 mg/day treatment 
improved most efﬁ  cacy measures. Compared to placebo, 
patients treated with duloxetine showed signiﬁ  cant improve-
ment in the FIQ total and stiffness score, the BPI average pain 
severity and pain interference score, the CGIS, and the PGAI. 
Also several quality of life measures (QLDS total score, 
SDS total score, SF-36) improved in the duloxetine group Neuropsychiatric Disease and Treatment 2008:4(3) 527
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compared to placebo. Furthermore, duloxetine signiﬁ  cantly 
reduced the tender point count and the tender point pain 
thresholds. A reduction of at least 50% in the FIQ pain score 
was achieved in 27.7% of the duloxetine group and in 16.7% 
of the placebo group, but this difference failed to reach sig-
niﬁ  cance (p = 0.06). Interestingly, a gender difference was 
found with a lack of response in men; however, this ﬁ  nding 
may be biased by the small number of male subjects in the 
duloxetine (n = 12 out of 104 patients) and placebo groups 
(n = 11 out of 103 patients). It has to be noted that reduction 
of pain severity by duloxetine was independent of accom-
panying major depression, but regression analysis showed 
a small indirect treatment effect through improvement in 
depressive symptoms.
This RCT was of excellent quality reaching a Jadad score 
of 5. The Jadad score is a validated numerical score ranging 
from 0 to 5 assigned as a rough measure of study design/
reporting quality (0 being weakest and 5 being strongest) 
(Jadad et al 1996). A power calculation was performed as 
well as an intention to treat analysis with further ANOVA. 
Data were adjusted for multiple testing and were suitable 
for meta-analysis.
Duloxetine 60 mg/day versus 
120 mg/day
The second trial also was a multi-center RCT with parallel 
design lasting over 12 weeks (Arnold et al 2005). Of 745 
patients screened, 354 (47.5%) were suitable for the study 
and were randomized. Of these, 215 (60.7%) completed the 
study. The placebo group consisted of 120 and the duloxetine 
group of 234 patients. In the placebo group, 68 participants 
(56.7%) completed the trial and in the duloxetine group, 147 
(60.5%). Mean age of patients was 49.6 years, all patients 
were women, 89.5% were Caucasian.
Two treatment regimes were investigated. Duloxetine 
was applied in a dosage of 60 mg once daily or 120 mg 
(60 mg twice a day). Patients randomized for the higher dose 
started with 60 mg/day and titrated to 120 mg/day within 
3 days. Patient assessment was performed during 7 visits. 
The permitted analgesic rescue medication consisted of 
paracetamol (up to 2 g/day), and acetyl salicylic acid (up to 
325 mg/day) for cardiac prophylaxis. All other analgesics 
and medication with central nervous system activity were 
excluded, with a wash out period identical to the ﬁ  rst RCT. Of 
the study population, 26% reported current major depression. 
A number of exclusion criteria were observed such as
concomitant rheumatologic and cardiac diseases, and being 
refractory to treatment, in the investigator’s opinion.
The aim of this RCT was to conﬁ  rm the results of the 
ﬁ  rst study, and to examine further the efﬁ  cacy and safety of 
duloxetine in the treatment of FMS symptoms including a 
lower dose. The primary outcome measure was pain severity 
as assessed by the BPI average pain severity score. Secondary 
outcome measures were the BPI interference score, the FIQ 
total score, the CGIS, the Hamilton Depression Rating Scale 
(HAMD), and the Patient Global Impression of Improvement 
(PGII). Quality of life measures covered the QLDS, the SDS, 
and the SF-36. Additionally, the tender point count and the 
mean tender point pain threshold were determined.
Patients treated with duloxetine more frequently reported 
adverse effects (92.4% duloxetine 60 mg; 90.5% duloxetine 
120 mg) than patients in the placebo group (79.2%). Patients 
in both duloxetine groups reported nausea, xerostomia (dry 
mouth), constipation, decreased appetite, and anorexia more 
frequently than patients in the placebo group. Diarrhea and 
nasopharyngitis were reported more frequently by patients 
treated with duloxetine 60 mg/day than those treated with 
placebo. Somnolence, increased sweating, feeling jittery, 
and nervousness were reported more often by patients in the 
duloxetine 120 mg/day group than by those treated with placebo. 
More patients in the duloxetine 60 mg/day reported insomnia 
during the discontinuation phase compared to placebo-treated 
patients. There were more study drop outs due to side effects 
in both duloxetine groups (about 22%) than in the placebo 
group (11.7%), while overall more patients discontinued the 
study in the placebo group (43%) compared to duloxetine 
60 mg/day (35%) and duloxetine 120 mg/day (39%).
In both duloxetine treatment groups signiﬁ  cantly more 
patients showed a 50% decrease in the BPI average 
pain severity score compared to placebo (41% duloxetine 
60 mg/day and 120 mg/day each; 23% placebo). Also the 
BPI-interference scores and the scores assessed with the FIQ, 
the CGIS, and the PGII decreased signiﬁ  cantly more in the 
treatment groups with both dosages than in the placebo group 
without difference between the two dosages of duloxetine. 
Quality of life improved under duloxetine 60 mg/day and 
120 mg/day. Taken together, both dosages were equally 
effective in reducing pain and improving patients’ quality of 
life without signiﬁ  cant intergroup difference, and again the 
reduction in pain severity was independent of accompanying 
major depression. For the tender points, however, different 
outcomes were observed with the two drug dosages. Only 
duloxetine 120 mg/day signiﬁ  cantly reduced tender point 
count and increased tender point pain thresholds.
This RCT was also of excellent quality with a Jadad 
score of 5. A power calculation was performed as well as Neuropsychiatric Disease and Treatment 2008:4(3) 528
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an intention to treat analysis with further ANOVA. Data 
were adjusted for multiple testing and were suitable for 
meta-analysis.
Summary
FMS is a lifelong disorder, which requires long-term 
treatment that has to address various symptoms. The 
pathophysiological background is unclear and causal treat-
ment options are not available. There is a growing body of 
pharmacological studies in search of the most proper drug 
to relieve symptoms of FMS with minimum adverse effects. 
The most commonly used drugs are antidepressants, which 
are effective in mood disorders and pain – two symptoms 
frequently combined in FMS. Serotonin and norepinephrine 
are involved in endogenous central analgesic pathways 
(Millan 2002) and have antidepressant action. Therefore 
a beneficial effect on symptoms in patients with FMS 
is expected using SNRI such as duloxetine. In the two 
RCTs on duloxetine for FMS, the investigated dosages of 
60 mg/day and 120 mg/day were equally effective in pain 
relief independent of the drug’s antidepressant action dur-
ing the 12 weeks of observation. As secondary outcome, 
improvement of patients’ quality of life was achieved. The 
higher dosage of 120 mg/day was associated with more 
adverse effects, but led to an additional reduction of tender 
point count and tender point pain thresholds. It is important 
to note that the side effects in the second trial, including 
a high percentage of nausea, most probably were due to 
the different titration regimes used: while in the ﬁ  rst trial 
patients started with 20 mg/day and titrated to 120 mg/day 
within 2 weeks, in the second trial patients started with 
60 mg/day and reached 120 mg/day within 3 days. Therefore, 
the motto for safe duloxetine treatment should be “start low 
and go slow” – as is true for most antidepressants. As with 
every drug, contraindications and possible drug interactions 
should be considered before prescribing duloxetine.
In both RCTs a considerable number of inclusion and 
exclusion criteria were observed leading to the question of 
whether this might have inﬂ  uenced the outcome measures 
by generating a selected group of patients. In particular, the 
exclusion of patients who were obviously difﬁ  cult to treat 
(failure to respond to more than two different classes of 
antidepressants for depression or FMS in the 2004 trial and 
being treatment refractory in the investigator’s judgement 
in the 2005 trial) might reduce the impact ot the trials for 
general practice.
Although the two RCTs on duloxetine give evidence for 
the effectiveness of duloxetine in FMS, it has to be taken 
into account that the reduction in the main symptom “pain” 
was only moderate in both studies (27.8% and 43.8%). These 
percentages are in line with the moderate efﬁ  cacy of all drugs 
tested for FMS so far, including the tricyclic antidepressant 
amitriptyline. However, given a side effect proﬁ  le that is in 
part different from that of tricyclic antidepressants, SNRI 
may be a useful alternative in FMS. One further study inves-
tigated milnacipran, another SNRI for patients with FMS, 
and found efﬁ  cacy in the reduction of pain when applying 
a daily dosage of 200 mg, althouhg no effect was seen on 
sleep disturbances. No severe adverse effects were reported 
(Vitton et al 2004). Further trials using other SNRI and trials 
combining drugs with different mechanisms of action should 
be performed, with the aim of achieving more marked pain 
reduction and improvement of physical function with mini-
mum adverse effects.
As for all antidepressants investigated in the context 
of FMS, only short-term data are available for duloxetine, 
mainly collected in Caucasian women. Therefore, long-term 
trials and studies investigating the effect of duloxetine in male 
FMS patients and non-Caucasians are needed to expand the 
knowledge about the possible effects and side effects of this 
drug. Given the good tolerability and at least moderate effect 
on pain and quality of life in patients with FMS, duloxetine 
is a valuable addition to the range of pharmacological treat-
ment options for FMS.
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